Histopathologic Assessment of Suspected Idiopathic Pulmonary Fibrosis: Where We Are and Where We Need to Go.


Journal

Archives of pathology & laboratory medicine
ISSN: 1543-2165
Titre abrégé: Arch Pathol Lab Med
Pays: United States
ID NLM: 7607091

Informations de publication

Date de publication:
01 12 2020
Historique:
accepted: 18 03 2020
pubmed: 3 7 2020
medline: 12 1 2021
entrez: 3 7 2020
Statut: ppublish

Résumé

Accurate diagnosis of idiopathic pulmonary fibrosis (IPF) requires multidisciplinary diagnosis that includes clinical, radiologic, and often pathologic assessment. In 2018, the American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and the Latin American Thoracic Society (ATS/ERS/JRS/ALAT) and the Fleischner Society each published guidelines for the diagnosis of IPF, which include criteria for 4 categories of confidence of a histologic usual interstitial pneumonia (UIP) pattern. To (1) identify the role of the guidelines in pathologic assessment of UIP; (2) analyze the 4 guideline categories, including potential areas of difficulty; and (3) determine steps the Pulmonary Pathology Society and the greater pulmonary pathology community can take to improve current guideline criteria and histopathologic diagnosis of interstitial lung disease. Data were derived from the guidelines, published literature, and clinical experience. Both guidelines provide pathologists with a tool to relay to the clinician the likelihood that a biopsy represents UIP, and serve as an adjunct, not a replacement, for traditional histologic diagnosis. There are multiple challenges with implementing the guidelines, including (1) lack of clarity on the quantity and quality of histologic findings required, (2) lack of recognition that histologic features cannot be assessed independently, and (3) lack of guidance on how pathologists should incorporate clinical and radiographic information. Current criteria for "probable UIP" and "indeterminate for UIP" hinder accurate reflection of the likelihood of IPF. These challenges highlight the need for further morphologic-based investigations in the field of pulmonary pathology.

Identifiants

pubmed: 32614648
pii: 442284
doi: 10.5858/arpa.2020-0052-RA
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1477-1489

Informations de copyright

© 2020 College of American Pathologists.

Auteurs

Maxwell L Smith (ML)

From the Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale (Smith, Colby, Leslie, Larsen, Tazelaar).

Lida P Hariri (LP)

the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Hariri, Mino-Kenudson).

Mari Mino-Kenudson (M)

the Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston (Hariri, Mino-Kenudson).

Sanja Dacic (S)

the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dacic).

Richard Attanoos (R)

School of Medicine, Cardiff University, Cardiff, United Kingdom (Attanoos).

Alain Borczuk (A)

the Department of Pathology, Weill Cornell Medicine, New York, New York (Borczuk).

Thomas V Colby (TV)

From the Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale (Smith, Colby, Leslie, Larsen, Tazelaar).

Wendy Cooper (W)

Tissue Pathology and Diagnostic Oncology, NSW Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia (Cooper).
Sydney Medical School, University of Sydney, Sydney, NSW, Australia (Cooper).

Kirk D Jones (KD)

the Department of Pathology, University of California San Francisco, San Francisco (Jones).

Kevin O Leslie (KO)

From the Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale (Smith, Colby, Leslie, Larsen, Tazelaar).

Annabelle Mahar (A)

Royal Prince Alfred Hospital, Camperdown, NSW, Australia (Mahar).

Brandon T Larsen (BT)

From the Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale (Smith, Colby, Leslie, Larsen, Tazelaar).

Alberto Cavazza (A)

Pathology Unit, AUSL/IRCCS di Reggio Emilia, Reggio Emilia, Italy (Cavazza).

Jun Fukuoka (J)

the Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan (Fukuoka).

Anja C Roden (AC)

the Department of Laboratory Medicine and Pathology, Mayo Clinic Rochester, Rochester, Minnesota (Roden).

Lynette M Sholl (LM)

the Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (Sholl).

Henry D Tazelaar (HD)

From the Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale (Smith, Colby, Leslie, Larsen, Tazelaar).

Andrew Churg (A)

the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Churg).

Mary Beth Beasley (MB)

and the Department of Pathology, Mount Sinai Health System, Icahn School of Medicine, New York, New York (Beasley).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH